We are live on ! Find out more
PVCT

Provectus Biopharmaceuticals
PVCT

Delisted

PVCT was delisted on the 13th of October, 2016.

3 hedge funds and large institutions have $5K invested in Provectus Biopharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

62% less capital inflows, than outflows

Capital inflows: $758 | Capital outflows: $2K

63% less funds holding

Funds holding: 8 → 3 (-5)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 4

Holders
3
Holders Change
-5
Holders Change %
-62.5%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Focused Wealth Management
Focused Wealth Management
New York
+$758

Top Sellers

Rank Fund Capital Flow
1
Cutter & Co Brokerage
Cutter & Co Brokerage
Missouri
-$2K

PVCT Hedge Fund Activity: Q1 2017 in Review

3 of the 4,036 institutional investors tracked by Wall St. Rank reported a position in Provectus Biopharmaceuticals (PVCT) for Q1 2017, worth a combined $5K — up 25% from $4K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of PVCT and 0 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was Focused Wealth Management, adding an estimated $758. The largest seller was Cutter & Co Brokerage, exiting entirely with an estimated $2K sold.

  • 3 institutional investors held Provectus Biopharmaceuticals (PVCT) as of Q1 2017, down from 8 in Q4 2016.
  • Funds reported $5K of Provectus Biopharmaceuticals stock for Q1 2017, up 25% quarter-over-quarter.
  • 0 funds opened new Provectus Biopharmaceuticals positions in Q1 2017 and 4 closed out, a net change of -4 holders.
  • The largest Provectus Biopharmaceuticals buyer in Q1 2017 was Focused Wealth Management, an estimated $758 added.
  • The largest Provectus Biopharmaceuticals seller in Q1 2017 was Cutter & Co Brokerage, an estimated $2K sold.

Based on aggregated 13F filings for Q1 2017.